Press release content from Globe Newswire. The AP news staff was not involved in its creation. Appendix 4C Quarterly Activity Report Mesoblast LimitedApril 30, 2021 GMT NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the third quarter ended March 31, 2021. “We are very excited about the top-line results announced today from the trial of remestemcel-L in patients on mechanical ve...